Long-term data from the phase 3 MANUEVER trial (NCT05804045) demonstrated that treatment with pimicotinib (ABSK021) led to robust and durable responses in patients with tenosynovial giant cell tumor (TGCT).1
Findings presented at the
Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT
